⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
globenewswire.com
GSK
JNJ
PFE
REGN
SNY
AMTX
ATHA
TMO
GILD
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
prnewswire.com
IDT
SNY
Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prnewswire.com
REGN
NVS
ROG
BIIB
CHRS
SNY
APLS
BHC
IONS
Sanofi Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map
globenewswire.com
SNY
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
globenewswire.com
SNY
REGN
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
globenewswire.com
REGN
SNY
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
globenewswire.com
ALV
SNY
LLY
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
globenewswire.com
SNY
More Than 30 Million Americans Living with Rare Diseases
prnewswire.com
AMGN
SNY
AGIO
ASND
DVA
INCY
NVS
PFE
REGN
UCB